Compare VCEL & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | JANX |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1997 | 2021 |
| Metric | VCEL | JANX |
|---|---|---|
| Price | $39.00 | $13.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $57.50 | ★ $60.27 |
| AVG Volume (30 Days) | 575.4K | ★ 2.3M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 236.54 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $258,716,999.00 | $10,000,000.00 |
| Revenue This Year | $17.86 | N/A |
| Revenue Next Year | $18.55 | N/A |
| P/E Ratio | $150.36 | ★ N/A |
| Revenue Growth | ★ 14.05 | N/A |
| 52 Week Low | $29.24 | $13.28 |
| 52 Week High | $63.00 | $61.59 |
| Indicator | VCEL | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 58.62 | 26.28 |
| Support Level | $35.33 | $13.82 |
| Resistance Level | $38.15 | $14.49 |
| Average True Range (ATR) | 1.43 | 0.47 |
| MACD | 0.12 | 0.36 |
| Stochastic Oscillator | 99.29 | 1.56 |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.